Table 1.
IL-17A and IL-17A/F inhibitors | Secukinumab |
Ixekizumab | |
IL-17A and IL-17F inhibitors | Bimekizumab |
IL-17RA inhibitors | Brodalumab |
IL-23 inhibitors | Tildrakizumab |
Risankizumab | |
Ustekinumab | |
IL-17A and TNF-α inhibitors | ABT-122 |
IL-17A and IL-17A/F inhibitors | Secukinumab |
Ixekizumab | |
IL-17A and IL-17F inhibitors | Bimekizumab |
IL-17RA inhibitors | Brodalumab |
IL-23 inhibitors | Tildrakizumab |
Risankizumab | |
Ustekinumab | |
IL-17A and TNF-α inhibitors | ABT-122 |